Previous 10 | Next 10 |
Danaher Corporation (DHR) Q2 2022 Earnings Conference Call July 21, 2022 8:00 AM ET Company Participants John Bedford – Vice President-Investor Relations Rainer Blair – President and Chief Executive Officer Matt McGrew – Executive Vice Presid...
The following slide deck was published by Danaher Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Danaher Corporation 2022 Q2 - Results - Earnings Call Presentation
Danaher ( NYSE: DHR ) Q2 total sales grew to $7.75B but COVID-19 related testing products showed a decline. The company saw a -1.5% Y/Y negative impact of COVID-19 related testing, compared to Q2 2021. For H1 there was -2.5% decline, compared to the same period in the pr...
Danaher press release ( NYSE: DHR ): Q2 Non-GAAP EPS of $2.76 beats by $0.42 . Revenue of $7.75B (+7.3% Y/Y) beats by $460M . For 3Q22, the company anticipates that non-GAAP base business core revenue growth will be in the high-single digit percent range. F...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
Danaher Reports Second Quarter 2022 Results PR Newswire WASHINGTON, D.C. , July 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022. All results in this release reflect only co...
Danaher ( NYSE: DHR ) is scheduled to announce Q2 earnings results on Thursday, July 21st, before market open. The consensus EPS Estimate is $2.34 (-4.9% Y/Y) and the consensus Revenue Estimate is $7.3B (+1.1% Y/Y). Over the last 2 years, DHR has beaten EPS estimates...
Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...
After a summer lull, earnings season accelerates into mid-July with a spate of reports from some of the world’s most high-profile companies. This includes two big names tied to Elon Musk -- Tesla ( NASDAQ: TSLA ) and Twitter ( NYSE: TWTR ). The schedule also inclu...
The NZS Capital Growth Equity strategy was down 23.44% net of fees in the second quarter of 2022. We believe companies that maximize non-zero-sum outcomes for all of their constituents, including employees, customers, suppliers, society, and the environment, will also maximize long-te...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...